Entry Point Capital, LLC Mirum Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 7,878 shares of MIRM stock, worth $562,804. This represents 0.23% of its overall portfolio holdings.
Number of Shares
7,878
Previous 7,266
8.42%
Holding current value
$562,804
Previous $369,000
56.37%
% of portfolio
0.23%
Previous 0.2%
Shares
5 transactions
Others Institutions Holding MIRM
# of Institutions
291Shares Held
57.5MCall Options Held
86.1KPut Options Held
105K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$485 Million21.07% of portfolio
-
Janus Henderson Group PLC London, X05MShares$357 Million0.18% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$231 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.55MShares$182 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.52MShares$180 Million3.41% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $2.63B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...